To further explore the applicability of SynCav1 therapy in AD, we also examined the effects of SynCav1 hippocampal delivery in a recently developed AD mouse model carrying three human APP mutations, termed AppNL−G−F/NL−G−F (APPKI), at symptomatic age. Here, APP is linked to Alzheimer disease.